CoChat

The gene therapy journey for hemophilia: are we there yet?

Open access
High, Katherine A. · 2012 · Blood
Cited by 55

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Since the isolation and characterization of the genes for FVIII and FIX some 30 years ago, a longstanding goal of the field has been development of successful gene therapy for the hemophilias. In a landmark study published in 2011, Nathwani et al demonstrated successful conversion of severe hemophilia B to mild or moderate disease in 6 adult males who underwent intravenous infusion of an adeno-associated viral (AAV) vector expressing factor IX. These 6 subjects have now exhibited expression of FIX at levels ranging from 1% to 6% of normal for periods of > 2 years. This review discusses obstacles that were overcome to reach this goal and the next steps in clinical investigation. Safety issues that will need to be addressed before more widespread use of this approach are discussed. Efforts to extend AAV-mediated gene therapy to hemophilia A, and alternate approaches that may be useful for persons with severe liver disease, who may not be candidates for gene transfer to liver, are also discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-05-423210

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 34

  1. Nathwani, 2011, Adeno-associated viral vector mediated gene transfer for hemophilia B., Blood, 118, 4, 10.1182/blood.V118.21.5.5 · DOI
  2. Shapiro, 2012, Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients., Blood, 119, 666, 10.1182/blood-2011-07-367003 · DOI · Paper page
  3. Ostergaard, 2011, Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide., Blood, 118, 2333, 10.1182/blood-2011-02-336172 · DOI · Paper page
  4. Aiuti, 2009, Gene therapy for immunodeficiency due to adenosine deaminase deficiency., N Engl J Med, 360, 447, 10.1056/NEJMoa0805817 · DOI · Paper page
  5. Herzog, 1998, Long-term phenotypic correction of hemophilia B in a large animal model by AAV-mediated gene transfer., Blood, 92, 153a
  6. Boyce, 2001, Trial halted after gene shows up in semen., Nature, 414, 677, 10.1038/414677a · DOI
  7. Arruda, 2001, Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males., Mol Ther, 4, 586, 10.1006/mthe.2001.0491 · DOI · Paper page
  8. Favaro, 2009, Host and vector-dependent effects on the risk of germline transmission of AAV vectors., Mol Ther, 17, 1022, 10.1038/mt.2009.56 · DOI · Paper page
  9. Schuettrumpf, 2006, Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial., Mol Ther, 13, 1064, 10.1016/j.ymthe.2006.03.002 · DOI
  10. Berns, 2007, Parvoviridae.
  11. Calcedo, 2009, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses., J Infect Dis, 199, 381, 10.1086/595830 · DOI · Paper page
  12. Nathwani, 2007, Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates., Blood, 109, 1414, 10.1182/blood-2006-03-010181 · DOI · Paper page
  13. Sommer, 2003, Quantification of adeno-associated virus particles and empty capsids by optical density measurement., Mol Ther, 7, 122, 10.1016/S1525-0016(02)00019-9 · DOI · Paper page
  14. Finn, 2010, Factor IX-R338L (FIX Padua) as a novel alternative for the treatment of canine severe hemophilia B., Mol Ther, 18, S239, 10.1016/S1525-0016(16)38056-X · doi:10.1016/s1525-0016(16)38056-x
  15. Rutledge, 1997, Adeno-associated virus vector integration junctions., J Virol, 71, 8429, 10.1128/JVI.71.11.8429-8436.1997 · DOI · Paper page
  16. Nakai, 1999, Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver., J Virol, 73, 5438, 10.1128/JVI.73.7.5438-5447.1999 · DOI · Paper page
  17. Donsante, 2001, Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors., Gene Ther, 8, 1343, 10.1038/sj.gt.3301541 · DOI · Paper page
  18. Li, 2011, Assessing the potential for AAV vector genotoxicity in a murine model., Blood, 117, 3311, 10.1182/blood-2010-08-302729 · DOI · Paper page
  19. Chao, 2000, Sustained expression of human factor VIII in mice using a parvovirus-based vector., Blood, 95, 1594, 10.1182/blood.V95.5.1594.005k34_1594_1599 · DOI · Paper page
  20. Jiang, 2006, Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs., Blood, 108, 107, 10.1182/blood-2005-12-5115 · DOI · Paper page
  21. Sabatino, 2011, Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors., Mol Ther, 19, 442, 10.1038/mt.2010.240 · DOI · Paper page
  22. Ward, 2011, Codon optimization of human factor VIII cDNAs leads to high-level expression., Blood, 117, 798, 10.1182/blood-2010-05-282707 · DOI · Paper page
  23. Montgomery, 2010, Alternative strategies for gene therapy of hemophilia., Hematology Am Soc Hematol Educ Program, 2010, 197, 10.1182/asheducation-2010.1.197 · DOI
  24. Greene, 2010, In vivo efficacy of platelet-delivered, high specific activity factor VIII variants., Blood, 116, 6114, 10.1182/blood-2010-06-293308 · DOI · Paper page
  25. Sun, 2008, Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX., Blood, 112, 4532, 10.1182/blood-2008-01-131417 · DOI · Paper page
  26. Herzog, 1999, Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector., Nat Med, 5, 56, 10.1038/4743 · DOI · Paper page
  27. Arruda, 2010, Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B., Blood, 115, 4678, 10.1182/blood-2009-12-261156 · DOI · Paper page
  28. Kay, 2000, Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector., Nat Genet, 24, 257, 10.1038/73464 · DOI · Paper page
  29. Yarovoi, 2003, Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment., Blood, 102, 4006, 10.1182/blood-2003-05-1519 · DOI · Paper page
  30. Shi, 2006, Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies., J Clin Invest, 116, 1974, 10.1172/JCI28416 · DOI · Paper page
  31. Matsui, 2011, A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of hemophilia A., Mol Ther, 19, 723, 10.1038/mt.2010.290 · DOI · Paper page
  32. Brown, 2007, In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance., Blood, 109, 2797, 10.1182/blood-2006-10-049312 · DOI · Paper page
  33. Mates, 2009, Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates., Nat Genet, 41, 753, 10.1038/ng.343 · DOI · Paper page
  34. Hedner, 2012, Activated factor VII: my story., Haemophilia, 18, 147, 10.1111/j.1365-2516.2012.02753.x · doi:10.1111/j.1365-2516.2012.02753.x

Cited by

See all 55

Metadata

Authors
High, K. A.
Venue
Blood
Published
2012-11-29
Volume
120
Issue
23
Pages
4482-4487
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2166705256
Cited by
55
References
25
FWCI
6.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The gene therapy journey for hemophilia: are we there yet? https://app.cochat.ai/papers/10.1182/blood-2012-05-423210
The paper
High, K. A. (2012). The gene therapy journey for hemophilia: are we there yet? Blood. https://doi.org/10.1182/blood-2012-05-423210

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.